FY2025 · ended Dec 31, 2025 · Revenue $14.34B, +1.0% YoY · Filed Feb 4, 2026
Regeneron Pharmaceuticals, Inc. (REGN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $14.3 billion and net income of $4.5 billion. Free cash flow was $4.1 billion. As of Sep 30, 2026 it held $18.9 billion in cash and investments and $2.7 billion in total debt.
Revenue (TTM)
$16.90B
+18.6% vs year-ago TTM
Net income (TTM)
$4.82B
+5.2% vs year-ago TTM
Operating cash flow (TTM)
$4.85B
-4.4% vs year-ago TTM
Free cash flow (TTM)
$3.83B
-9.4% vs year-ago TTM
EPS (TTM)
$45.17
+8.6% vs year-ago TTM
Dividend per share
None
Shares outstanding
91.78M
+4.6% vs prior year
Net cash
$16.15B
as of Sep 30, 2026
Operating margin
28.8%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- REGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- NY
- Headquarters
- Tarrytown, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 872589
- Former names
- REGENERON PHARMACEUTICALS INC (until Jun 19, 2019)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $14.3B | $14.2B | $13.1B | $12.2B | $16.1B |
| Operating income | $3.6B | $4.0B | $4.0B | $4.7B | $8.9B |
| Net income | $4.5B | $4.4B | $4.0B | $4.3B | $8.1B |
| Diluted EPS | $41.48 | $38.34 | $34.77 | $38.22 | $71.97 |
| Operating cash flow | $5.0B | $4.4B | $4.6B | $5.0B | $7.1B |
| Free cash flow | $4.1B | $3.7B | $3.9B | $4.4B | $6.5B |
| Total assets | $40.6B | $37.8B | $33.1B | $29.2B | $25.4B |
| Total liabilities | $9.3B | $8.4B | $7.1B | $6.6B | $6.7B |
| Stockholders' equity | $31.3B | $29.4B | $26.0B | $22.7B | $18.8B |
| Cash and investments | $18.9B | $17.9B | $16.2B | $14.3B | $12.5B |
| Total debt | $3.0B | $2.9B | $2.8B | $2.7B | $2.7B |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Oct 30, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Results of operations
|
Oct 30, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Material agreement, Results of operations, Other events
|
Oct 6, 2026 | Oct 1, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 30, 2026 | Sep 24, 2026 |
| 10-Q | Quarterly report | Jul 30, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2026 | Jul 30, 2026 |
All 1000 Regeneron Pharmaceuticals, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.